Dyne Therapeutics DYN's latest lobbying report covers Q2 2026, at $40K. Its first report covers Q2 2026; the issues it reports most are Health Issues.

Dyne TherapeuticsDYN

Dyne Therapeutics stock page

Latest quarter: $40K; Q2 2026 · 1 reports
Last 12 months: $40K; Last 1 quarters
vs last quarter: No record; Q2 2026 against the quarter before
First report: Q2 2026; The first quarter a report named it

Lobbying by quarter

Policy issues the reports name

Health issues1 reports

A report that names several issues counts once for each.

Who was lobbied

HOUSE OF REPRESENTATIVES1 reports

Firms it paid

Firm
W Strategies	$40K	1 quarters

Former officials lobbying for it

	Former position	Firm
DARREN WILLCOX	Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director	W Strategies	Q2 2026

Lobbying reports

	Filed by		Issues
07/20for Q2	W Strategies	$40K	Health issues
04/07for Q2	W Strategies	Under $5,000	Health issues